CO5200837A1 - vaccines - Google Patents



Publication number
CO5200837A1 CO00072096A CO00072096A CO5200837A1 CO 5200837 A1 CO5200837 A1 CO 5200837A1 CO 00072096 A CO00072096 A CO 00072096A CO 00072096 A CO00072096 A CO 00072096A CO 5200837 A1 CO5200837 A1 CO 5200837A1
Prior art keywords
polyoxyethylene sorbitan
Prior art date
Application number
Other languages
Spanish (es)
Martin Friede
Philippe Hermand
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9922703.5A priority Critical patent/GB9922703D0/en
Priority to GB0016685A priority patent/GB0016685D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5200837A1 publication Critical patent/CO5200837A1/en



    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose


El uso de una combinación de un éster de polioxietilensorbitano y un octoxinol en la preparación de un coadyuvante para aplicación a una superficie mucosa de un paciente.1Un procedimiento para producir una vacuna, comprendiendo el procedimiento mezclar (a) un éster poxietilensorbitano, (b) un octoxinol y (c) un antígeno, y proporcionar la vacuna en forma de una dosis de vacuna para administración en mucosa.1Un dispositivo de pulverización o aerosol, más particularmente un dispositivo de dos dosis, rellenado con una vacuna que comprende un éster de polioxietilensorbitano, un octoxinol y un antígeno.1Un procedimiento para tratar un mamífero que padece o susceptible de una infección patogénica, o cáncer, o alergia, comprendiendo dicho procedimiento la administración a la mucosa del mamífero de una cantidad segura y efectiva de una composición de vacuna que comprende un éster de polioxietilensorbitano, un octoxinol y un antígeno. The use of a combination of a polyoxyethylene sorbitan ester and an octoxynol in the preparation of an adjuvant for application to a mucosal surface of a paciente.1Un process for producing a vaccine, the method mixing (a) an ester comprising poxietilensorbitano, (b) an octoxynol and (c) an antigen, and provide the vaccine in the form of a dose of vaccine for administration mucosa.1Un or aerosol spray device, more particularly a two-dose device, filled with a vaccine comprising a polyoxyethylene sorbitan ester , an octoxynol and antígeno.1Un method of treating a mammal suffering from or susceptible to a pathogenic infection, or cancer, or allergy, said method comprising administering to the mucosa of mammal a safe and effective amount of a vaccine composition it comprises a polyoxyethylene sorbitan ester, an octoxynol and an antigen.
CO00072096A 1999-09-24 2000-09-22 vaccines CO5200837A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB9922703.5A GB9922703D0 (en) 1999-09-24 1999-09-24 Vaccine
GB0016685A GB0016685D0 (en) 2000-07-06 2000-07-06 Novel compounds

Publications (1)

Publication Number Publication Date
CO5200837A1 true CO5200837A1 (en) 2002-09-27



Family Applications (1)

Application Number Title Priority Date Filing Date
CO00072096A CO5200837A1 (en) 1999-09-24 2000-09-22 vaccines

Country Status (15)

Country Link
EP (1) EP1221971A2 (en)
JP (1) JP2003509473A (en)
CN (1) CN1391483A (en)
AU (1) AU765824B2 (en)
BR (1) BR0014282A (en)
CA (1) CA2383413A1 (en)
CO (1) CO5200837A1 (en)
CZ (1) CZ20021043A3 (en)
HU (1) HU0202885A3 (en)
IL (1) IL148672D0 (en)
MX (1) MXPA02003067A (en)
NO (1) NO20021433L (en)
PL (1) PL355163A1 (en)
TR (1) TR200200774T2 (en)
WO (1) WO2001021207A2 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463097A (en) 1996-01-04 1997-08-01 Rican Limited Helicobacter pylori bacterioferritin
MX357775B (en) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Nucleic acids and proteins from streptococcus groups a b.
AU2736502A (en) 2000-12-07 2002-06-18 Chiron Corp Endogenous retroviruses up-regulated in prostate cancer
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp Adjuvant compositions.
WO2003070909A2 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
EP1532161B1 (en) 2002-06-13 2012-02-15 Novartis Vaccines and Diagnostics, Inc. Vectors for expression of hml-2 polypeptides
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
AT437633T (en) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogenic compositions based on biodegradable microparticles containing a diphtheria and tetanus toxoid
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005032583A2 (en) 2003-10-02 2005-04-14 Chiron Srl Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US20080254065A1 (en) 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
CA2567446C (en) 2004-05-21 2018-01-02 Chiron Corporation Alphavirus vectors for respiratory pathogen vaccines
JP2008504292A (en) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド Compounds for immune enhancement
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0607374A2 (en) 2005-01-27 2009-09-01 Childrens Hosp & Res Ct Oakland vesicle-based vaccines gna1870 for broad-spectrum protection against disease caused by Neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
DE602006020738D1 (en) 2005-08-01 2011-04-28 Hisamitsu Pharmaceutical Co Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
CN101355960A (en) 2005-10-18 2009-01-28 诺华疫苗和诊断公司 Mucosal and systemic immunizations with alphavirus replicon particles
EP2368572A3 (en) 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ567980A (en) * 2005-11-04 2012-01-12 Novartis Vaccines & Diagnostic Administration routes (intranasal or mucosal and parenteral or intramuscular) for priming/boosting with influenza vaccines
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus antigen and support viral antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976559B1 (en) 2006-01-27 2017-01-04 Novartis Influenza Vaccines Marburg GmbH Influenza vaccines containing hemagglutinin and matrix proteins
US8535683B2 (en) 2006-03-22 2013-09-17 Abbott Biologicals B.V. Intranasal or inhalational administration of virosomes
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
US20100010199A1 (en) 2006-09-11 2010-01-14 Novartis Ag Making influenza virus vaccines without using eggs
WO2008068631A2 (en) 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
JP5275047B2 (en) * 2007-01-31 2013-08-28 久光製薬株式会社 Adjuvants and pharmaceutical formulations containing them for transdermal or transmucosal administration
ES2393162T3 (en) 2007-06-27 2012-12-19 Novartis Ag influenza vaccines with a reduced additive content
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2244695A1 (en) 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
NZ586430A (en) 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
RU2475496C2 (en) 2008-02-21 2013-02-20 Новартис Аг MENINGOCOCCAL fHBP POLYPEPTIDES
AU2009223613B2 (en) 2008-03-10 2014-09-25 Children's Hospital & Research Center At Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2010067286A2 (en) 2008-12-09 2010-06-17 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
MX2011007456A (en) 2009-01-12 2011-08-03 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria.
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
JP5830009B2 (en) 2009-04-14 2015-12-09 ノバルティス アーゲー Composition for immunizing against Staphylococcusaureus
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
DK2442826T3 (en) 2009-06-15 2015-09-21 Univ Singapore Influenza vaccine, composition and methods of using
JP2012532600A (en) 2009-07-07 2012-12-20 ノバルティス アーゲー Stored E. coli immunogen
SG178026A1 (en) 2009-07-15 2012-03-29 Novartis Ag Rsv f protein compositions and methods for making same
EP2464658B1 (en) 2009-07-16 2014-10-01 Novartis AG Detoxified escherichia coli immunogens
WO2011013034A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
NZ622048A (en) 2009-08-27 2015-10-30 Novartis Ag Hybrid polypeptides including meningococcal fhbp sequences
CA2846746A1 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
CA2779798C (en) 2009-09-30 2019-03-19 Novartis Ag Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
EP2515934B1 (en) 2009-12-22 2017-05-17 Celldex Therapeutics, Inc. Vaccine compositions
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
KR20130121699A (en) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 Interactive hybrid asynchronous computer game infrastructure
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
MX2013000163A (en) 2010-07-06 2013-03-05 Novartis Ag Norovirus derived immunogenic compositions and methods.
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2655389A2 (en) 2010-12-24 2013-10-30 Novartis AG Compounds
SI2667892T1 (en) 2011-01-26 2019-05-31 Glaxosmithkline Biologicals Sa Rsv immunization regimen
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
AU2012255971A1 (en) 2011-05-13 2013-05-02 Novartis Ag Pre-fusion RSV F antigens
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic compositions combination and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
ES2687129T3 (en) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Compositions and methods for assessing functional immunogenicity of vaccines against parvovirus
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
KR20190042760A (en) 2012-05-04 2019-04-24 화이자 인코포레이티드 Prostate-associated antigens and vaccine-based immunotherapy regimens
MX2014014067A (en) 2012-05-22 2015-02-04 Novartis Ag Meningococcus serogroup x conjugate.
JP2015522580A (en) 2012-07-06 2015-08-06 ノバルティス アーゲー Immunological compositions and the use thereof
TR201808684T4 (en) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Non-linear saccharide conjugates.
KR20150073943A (en) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. Immunogenic composition
RS56886B1 (en) 2012-11-30 2018-04-30 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
JP6114401B2 (en) 2013-10-31 2017-04-12 久光製薬株式会社 Adjuvant composition, the adjuvant formulations, and kits comprising the same
EP3096785A2 (en) 2014-01-21 2016-11-30 Pfizer Inc Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
MX2017009308A (en) 2015-01-15 2017-11-08 Pfizer Immunogenic compositions for use in pneumococcal vaccines.
JP2018521016A (en) 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトAffiris Ag IL-23-p19 vaccine
US20180186896A1 (en) 2015-07-07 2018-07-05 Affiris Ag Vaccines for the treatment and prevention of ige mediated diseases
PE6572018A1 (en) 2015-07-21 2018-04-17 Pfizer immunogenic compositions comprising capsular saccharide antigens conjugated kits comprising them and their uses
CA3005524A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
BR112018013967A2 (en) 2016-01-19 2019-02-05 Pfizer cancer vaccines
WO2018134693A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
NL8403195A (en) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogenic complexes and vaccines containing them.
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals

Also Published As

Publication number Publication date
NO20021433D0 (en) 2002-03-21
WO2001021207A2 (en) 2001-03-29
NO20021433L (en) 2002-05-21
JP2003509473A (en) 2003-03-11
AU765824B2 (en) 2003-10-02
CA2383413A1 (en) 2001-03-29
HU0202885A3 (en) 2004-07-28
AU7907000A (en) 2001-04-24
CZ20021043A3 (en) 2002-08-14
MXPA02003067A (en) 2002-09-30
TR200200774T2 (en) 2002-08-21
BR0014282A (en) 2002-05-21
CN1391483A (en) 2003-01-15
WO2001021207A3 (en) 2001-09-27
IL148672D0 (en) 2002-09-12
PL355163A1 (en) 2004-04-05
HU0202885A2 (en) 2002-12-28
EP1221971A2 (en) 2002-07-17

Similar Documents

Publication Publication Date Title
JO2381B1 (en) Formulations containing an antich holinergic drug for the treatment of chronic obstructive pulmonary disease
ES2552639T3 (en) combined use of valsartan blockers and calcium channel blockers for therapeutic purposes
ES2498095T3 (en) A pharmaceutical composition comprising fentanyl for cancer treatment or breakthrough pain by sublingual or acute administration
TWI232753B (en) Adjuvant compositions comprising QS-21,3D-MPL and CpG and vaccine compositions comprising the same
ES2130217T3 (en) Use of tyloxapol as dispersing and stabilizing nanoparticle.
CN1301132C (en) Molecular antigen array
AR077573A2 (en) Use of a TNF inhibitor and pharmaceutical composition comprising
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
PA8526101A1 (en) Sustained release formulations for growth hormone secretagogues
AR027034A1 (en) Composition for extended release oral dose
NO20121146L (en) Methods and compositions for treating hepatitis C virus
EA200601253A1 (en) Advantageously linear effervescent fentanyl dosage form for oral administration and methods
ES2162615T3 (en) Method for treating or preventing type 1 diabetes by oral administration of insulin.
CY1107870T1 (en) NEEDLES COATED with vaccine
NZ523408A (en) Human papilloma virus treatment
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
ES2178430T3 (en) Use of pharmaceutical compositions in Parodontology gellable.
ES2156839T1 (en) Medicament containing alginate and implant to treat fibrosis.
IL153463D0 (en) Pharmaceutical compositions comprising activated antibodies
MXPA02007229A (en) A method of administering a medicinal aerosol formulation.
NO20091022L (en) A vaccine comprising an oil in water emulsion adjuvant
ECSP055838A (en) Depot formulations of controlled release
TWI221768B (en) Pharmaceutical composition comprising histamine H1 receptor antagonist and histamine H3 receptor antagonist providing nasal decongestant effect
MXPA02008403A (en) Improvements in or relating to the delivery of oral drugs.
BR0311995A (en) Virus-like particles packaged for use as adjuvants: preparation and method of use

Legal Events

Date Code Title Description
FC Application refused